Cellular based immunotherapy for primary liver cancer

Table 2 Clinical therapeutic trials for engineered T cells against PLC

T cell engineering category	Trial Phase			Enrolled patients backgrounds			Trial information			Reference
T cell engineering category	I	II	III	Number.	Location	intervention	Antigen	comments	Identifier	Reference
TCR-T				7/ NCT04677088 10/ NCT02686372 10/ NCT02719782	China	HBV antigen specific TCR T cells	HBsAg	Safety; pulmonary metastases of HCC decreased; valuable prophylaxis against HCC relapse provided	NCT04677088 NCT02686372 NCT02719782	[68, 69]
CAR-T				30	China	GPC3-CAR-T cells	GPC3	HCC cells were eradicared and tumor growth was efficiently suppressed in PDX model	NCT03198546	[70]
				20	China	HCC: CD133-CAR-T cells iCCA: Cocktail treatment comprised with VEGF-CAR-T, PD-1 monoclonal antibody and CD133-CAR-T	CD133 VEGF	Clinical outcomes of dvanced HCC patients improved with manageable safety profile by CD133-CAR-T; Advanced iCCA patient acquired 8.5-month and 4.5-month partial response from VEGF-CAR-T and CD133-CAR-T, respectively.	NCT02541370	[71, 72]

Abbreviations for the table: TCR-T T cell receptor engineered T cells, CAR-T Chimeric antibody receptor engineered T Cells, GPC3 Glypican-3, CD133 Cluster of differentiation 133, VEGF Vascular endothelial growth factor, PD-1 Programmed cell death-1, HCC Hepatocellular carcinoma, iCCA Intrahepatic cholangiocarcinoma

ISSN: 1756-9966